ICs	Immune checkpoints
mAbs	monoclonal antibodies
ADCs	Antibody-drug conjugates
CAR-T cells	Chimeric antigen receptor T cells
B7-H3	B7 Homolog 3 Protein, CD276
CPIs	Immune checkpoint inhibitors
TME	Tumor microenvironment
TLT-2	Triggering receptors expressed in myeloid cells (TREM)-like transcript 2
IL-20Rα	IL-20 receptor subunit α
PLA2R1	Phospholipase A2 receptor 1
NFAT	Nuclear factor of activated T-cells
NF-kB	Nuclear factor kappa B
AP-1	Activator protein 1
TNF-a	Tumour Necrosis Factor alpha
FOXP3	Forkhead box P3
JAK/STAT3	Janus kinase/Signal transducer and activator of transcription
PI3K	Phosphoinositide 3-kinases
MMP	Matrix metalloproteinases
CA125/CA19-9	Cancer antigen125/Cancer antigen 19-9
EMT	Epithelial to mesenchymal transition
TGF-β1	Tumor growth factor-β1
TLR4	Toll-like receptor 4
DFS	Disease-free survival
MAPK/ERK	Mitogen-activated protein kinase/ extracellular signal-regulated kinase
CXCR4	C-X-C chemokine receptor type 4
NRF2	Nuclear factor erythroid 2–related factor 2
CDK4	Cyclin dependent kinase
TRAE	Treatment-related adverse events
DCIS	Ductal carcinoma in situ
NK	Naturall killer
mTOR	Mammalian target of rapamycin
RFS	Rellapse free survival
HGF	Hepatocyte growth factor
VEGF	Vascular and endothelial growth factor
TNM	Tumor, lymph nodes, metastasis
DC	Dendritic cell
TMB	Tumor mutational burden
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
PD-1	Programmed death-1
PD-L1	Programmed death ligand 1
MDSCs	Myeloid-derived suppressor cells
RFS	Relapse-free survival
OS	Overall survival
ORR	Objective response rates
IFNγ	Interferon gamma
DoR	Duration of response
LAG3	Lymphocyte activation gene 3